Edwards Lifesciences (NYSE:EW) issued an update on its FY19 earnings guidance on Thursday morning. The company provided EPS guidance of $5.05-5.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.19. The company issued revenue guidance of $3.9-4.3 billion, compared to the consensus revenue estimate of $4.16 billion.Edwards Lifesciences also updated its FY18 guidance to $4.60-4.75 EPS.
Edwards Lifesciences stock opened at $157.21 on Friday. The firm has a market capitalization of $34.14 billion, a PE ratio of 41.37, a PEG ratio of 2.15 and a beta of 0.90. Edwards Lifesciences has a fifty-two week low of $110.68 and a fifty-two week high of $175.00. The company has a current ratio of 2.31, a quick ratio of 1.85 and a debt-to-equity ratio of 0.18.
Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, October 23rd. The medical research company reported $1.07 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.05. The firm had revenue of $906.60 million for the quarter, compared to analysts’ expectations of $927.56 million. Edwards Lifesciences had a net margin of 20.67% and a return on equity of 30.11%. The business’s quarterly revenue was up 10.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.84 earnings per share. As a group, sell-side analysts anticipate that Edwards Lifesciences will post 4.7 earnings per share for the current year.
EW has been the topic of several research analyst reports. SunTrust Banks upped their price target on shares of Edwards Lifesciences to $200.00 and gave the stock a buy rating in a report on Friday, September 28th. Zacks Investment Research raised shares of Edwards Lifesciences from a hold rating to a buy rating and set a $185.00 price target on the stock in a report on Wednesday, September 26th. ValuEngine raised Edwards Lifesciences from a hold rating to a buy rating in a research note on Wednesday, September 19th. Cowen set a $190.00 target price on Edwards Lifesciences and gave the company a buy rating in a research note on Friday, November 30th. Finally, Jefferies Financial Group increased their target price on Edwards Lifesciences from $168.00 to $180.00 and gave the company a buy rating in a research note on Thursday. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus price target of $162.85.
In other Edwards Lifesciences news, VP Huimin Wang sold 3,800 shares of the company’s stock in a transaction dated Thursday, December 6th. The shares were sold at an average price of $155.87, for a total transaction of $592,306.00. Following the completion of the sale, the vice president now directly owns 35,024 shares in the company, valued at $5,459,190.88. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Schack Wesley W. Von sold 1,319 shares of the company’s stock in a transaction dated Thursday, November 29th. The shares were sold at an average price of $160.96, for a total transaction of $212,306.24. Following the sale, the director now owns 2,134 shares of the company’s stock, valued at $343,488.64. The disclosure for this sale can be found here. In the last three months, insiders sold 187,156 shares of company stock worth $27,603,513. 1.84% of the stock is owned by insiders.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.
Read More: Derivative
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.